AstraZeneca Pharma India Limited will launch Enhertu in January 2024 in India.

Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen.

The company has already received the Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Trastuzumab deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion (Enhertu).